Web报名链接见文末一、试验药物ct-707颗粒二、适应症克唑替尼耐药的晚期间变性淋巴瘤激酶突变阳性的非小细胞肺癌三、试验目的评价ct-707治疗克唑替尼耐药的晚期alk阳性nsclc患 … WebApr 17, 2024 · 中文通用名:CT-707颗粒: 用法用量:CT-707：规格25 mg/袋、50 mg/袋、100 mg/袋、200 mg/袋、250 mg/袋、300 mg/袋、450 mg/袋，淡黄色混悬型颗粒，适量温 …
CT-707临床试验,CT-707颗粒用于中国ALK阳性晚期非小 …
http://www.globecancer.com/zjft/show.php?itemid=579 WebOct 12, 2024 · This is a phase Ib/II, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics and antineoplastic activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer.The study consists of two parts, dose-escalation part and dose-expansion part. factorytalk recovery file storage
在健康受试者中评价食物对CT-707药代动力学影响的研究_爱康试药
http://akshiyao.com/index.php/ExpertTeam/876.html http://www.changbaicao.cn/trialsdetail-id-6056.html Web主要目的：在中国健康受试者中评价ct-707颗粒空腹和餐后状态下单次口服给药后的药代动力学特征，评价食物对ct-707生物利用度的影响。次要目的：评价ct-707在健康受试者中空腹和餐后状态下单次口服给药的安全性。 factorytalk parameter file editing